Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Exclusion Criteria

• •No prior therapy for pancreatic cancer
• •Previous treatment with bevacizumab or erlotinib
• •Evidence of duodenal invasion or gastric outlet obstruction
• •Presence of bleeding diathesis or coagulopathy
• •History or prior arterial thrombotic event
• •Conditions leading to inadequate gastrointestinal tract absorption
• •Poorly controlled diarrhea .
• •Presence of baseline proteinuria or renal dysfunction (CrCl \< 50 (Cockcroft-Gault equation)
• •Inadequately controlled hypertension
• •New York Heart Association (NYHA) Grade II or greater congestive heart failure
• •Clinically significant peripheral vascular disease
• •Presence of central nervous system or brain metastases
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
• •Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0
• •Pregnant or lactating females
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
• •Serious, non-healing wound, ulcer, or bone fracture
• •Inability to comply with study and/or follow-up procedures
• •Treatment for other carcinomas within the last five years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current PSA of \<1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry.
• •Comorbid conditions that would complicate safety or compliance